OSUR ORASURE TECHNOLOGIES INC

Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001116463
AI RATING
STRONG_SELL
78% Confidence

Investment Thesis

OraSure faces severe operational distress with 38% YoY revenue decline and significant operating losses (-$23.3M), despite maintaining a strong balance sheet with $177M cash and zero debt. Negative operating cash flow (-$13.9M) and deteriorating cash burn indicate business challenges that will erode the equity cushion without a successful turnaround. The company's substantial liquidity provides runway but masks fundamental business deterioration that makes current operations unsustainable.

Strengths

  • + Strong balance sheet with $313.3M stockholders equity and zero debt
  • + Substantial cash reserves of $177.0M providing operational runway
  • + Excellent liquidity ratios (5.46x current ratio, 4.77x quick ratio) for financial flexibility
  • + Reasonable gross margins at 42.3% indicating underlying product value

Risks

  • ! Severe revenue contraction of 38.1% YoY signals significant market or competitive headwinds in core business
  • ! Operating losses of $23.3M and negative operating cash flow of -$13.9M indicate inability to support current cost structure
  • ! Negative free cash flow of -$14.8M means equity is being consumed to fund operations unsustainably
  • ! Operating margin of -83.3% reflects fundamental unprofitability requiring restructuring or business model change

Key Metrics to Watch

Financial Metrics

Revenue
27.9M
Net Income
-22.4M
EPS (Diluted)
$-0.32
Free Cash Flow
-14.8M
Total Assets
379.2M
Cash
177.0M

Profitability Ratios

Gross Margin 42.3%
Operating Margin -83.3%
Net Margin -80.1%
ROE -7.1%
ROA -5.9%
FCF Margin -53.0%

Balance Sheet & Liquidity

Current Ratio
5.46x
Quick Ratio
4.77x
Debt/Equity
0.00x
Debt/Assets
17.4%
Interest Coverage
-135.28x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T09:02:12.359569 | Data as of: 2026-03-31 | Powered by Claude AI